[
  {
    "ts": "2025-12-23T03:11:42+00:00",
    "headline": "The Bull Case For Incyte (INCY) Could Change Following New Minjuvi And Zynyz Approvals In Europe And Japan",
    "summary": "In recent days, Incyte announced that the European Commission and Japan’s Ministry of Health, Labour and Welfare approved Minjuvi (tafasitamab) and Zynyz (retifanlimab) in new combination regimens for relapsed or refractory follicular lymphoma and advanced squamous cell carcinoma of the anal canal, expanding treatment options across major oncology markets. These approvals meaningfully broaden Incyte’s oncology footprint in Europe and Japan while deepening its presence in chemotherapy-free...",
    "url": "https://finance.yahoo.com/news/bull-case-incyte-incy-could-031142298.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "c2be2f28-23fd-37f6-80d2-bc2f17d0e78f",
      "content": {
        "id": "c2be2f28-23fd-37f6-80d2-bc2f17d0e78f",
        "contentType": "STORY",
        "title": "The Bull Case For Incyte (INCY) Could Change Following New Minjuvi And Zynyz Approvals In Europe And Japan",
        "description": "",
        "summary": "In recent days, Incyte announced that the European Commission and Japan’s Ministry of Health, Labour and Welfare approved Minjuvi (tafasitamab) and Zynyz (retifanlimab) in new combination regimens for relapsed or refractory follicular lymphoma and advanced squamous cell carcinoma of the anal canal, expanding treatment options across major oncology markets. These approvals meaningfully broaden Incyte’s oncology footprint in Europe and Japan while deepening its presence in chemotherapy-free...",
        "pubDate": "2025-12-23T03:11:42Z",
        "displayTime": "2025-12-23T03:11:42Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FqD7IP1YjoMtOLiC1foWBQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DnvRJ7zmyZqa8oFdfcLgCg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-incyte-incy-could-031142298.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-incyte-incy-could-031142298.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]